EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials

Lee X Li iD, Adel Shahnam iD, Ganessan Kichenadasse iD, Lewis Murray iD, Richard Woodman iD, Ahmad Y Abuhelwa iD, Natansh D Modi iD, Andrew Rowland iD, Ashley M Hopkins iD, Michael J Sorich iD

JNCI Cancer Spectrum · 03.03.2026 · 10 (2)

DOI: 10.1093/jncics/pkaf127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 07.01.2026. Verfasst von Lee X Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Immune Checkpoint Inhibitors, Treatment Effect Heterogeneity, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beat Cancer Research Fellowship from the Cancer Council South Australia, National Health and Medical Research Council, University of Sharjah Targeted Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment response to immune checkpoint inhibitors varies considerably, a phenomenon known as heterogeneity of treatment effect. Heterogeneity of treatment effect is explored via one-variable-at-a-time subgroup analyses in randomized controlled trials (RCTs), however, this method has limitations, which the risk-modeling approach seeks to address.

Methods

Applying the risk-modeling approach, individual patient data from 10 RCTs (6 supporting US Food and Drug Administration’s atezolizumab label: OAK, IMpower130, IMpower150, IMpower133, IMbrave150, IMspire150; 4 unlabeled indications: IMpower131, IMpower132, IMmotion151, and IMvigor211) were analyzed by an extreme gradient-boosting algorithm to predict pretreatment prognosis for overall survival. The predicted risk scores were evaluated as efficacy modifiers categorically (high-, intermediate-, low-risk groups) and continuously in Cox models with treatment-by-risk-group interaction terms. Sensitivity and exploratory analyses investigated absolute and meta-analyzed treatment effect and compared the results with established prognostic tools and treatment effect predictors. Statistical significance tests are 2-sided.

Results

Among the 10 RCTs (n = 7053), one trial (IMvigor211) showed statistically significant heterogeneity of treatment effect by pretreatment prognosis across all evaluations (risk groups, risk scores, sensitivity analyses: P < .001). Among other trials, no statistically significant heterogeneity of treatment effect was detected (risk group and risk score analysis interaction test: OAK P = .61 and P = .77; IMpower130 P = .13 and P = .52; IMpower131 P = .21 and P = .02; IMpower150 P = .14 and P = .36; IMpower133 P = .38 and P = .12; IMbrave150 P = .15 and P = .08; IMspire150 P = .24 and P = .6; IMpower132 P = .15 and P = .81; IMmotion151 P = .48 and P = .21, respectively).

Conclusions

The risk-modeling approach showed no clear link between pretreatment prognosis and immune checkpoint inhibitor efficacy in most RCTs, particularly those supporting atezolizumab’s Food and Drug Administration label. In IMvigor211, patients with better pretreatment prognosis were more likely to benefit from atezolizumab treatment for platinum-refractory metastatic urothelial carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicImmune Checkpoint InhibitorsTreatment Effect HeterogeneityNeoplasmsHumansPrognosisAntibodies, Monoclonal, HumanizedProportional Hazards Models

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.
  • Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, Australia.
  • Department of Medical Oncology, Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia.
  • Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, Australia.
  • Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
  • Clinical and Health Sciences, University of South Australia, Adelaide, Australia.

ORCID-Profile: Lee X Li, Adel Shahnam, Ganessan Kichenadasse, Lewis Murray, Richard Woodman, Ahmad Y Abuhelwa, Natansh D Modi, Andrew Rowland, Ashley M Hopkins, Michael J Sorich

Förderung

  • Beat Cancer Research Fellowship from the Cancer Council South Australia
  • National Health and Medical Research Council
  • University of Sharjah Targeted Research

Zitieren

APA

Li, L. X., Shahnam, A., Kichenadasse, G., Murray, L., Woodman, R., Abuhelwa, A. Y., Modi, N. D., Rowland, A., Hopkins, A. M., & Sorich, M. J. (2026). Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials. JNCI Cancer Spectrum, 10(2). https://doi.org/10.1093/jncics/pkaf127

Vancouver

Li LX, Shahnam A, Kichenadasse G, Murray L, Woodman R, Abuhelwa AY, et al. Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials. JNCI Cancer Spectrum. 2026;10(2). doi:10.1093/jncics/pkaf127

BibTeX
@article{Li2026,
  author = {Li, Lee X and Shahnam, Adel and Kichenadasse, Ganessan and Murray, Lewis and Woodman, Richard and Abuhelwa, Ahmad Y and Modi, Natansh D and Rowland, Andrew and Hopkins, Ashley M and Sorich, Michael J},
  title = {Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {2},
  doi = {10.1093/jncics/pkaf127}
}
Kostenlos starten →